Abstract

Correction to “Pharmacological Characterization of Olodaterol, a Novel Inhaled β2-Adrenoceptor Agonist, Exerting a 24-Hour-Long Duration of Action in Preclinical Models” var callbackToken='50544988FB765CB'; var subCode='aspet_sub'; Skip to main page content HOME CURRENT ISSUE ARCHIVE FEEDBACK SUBSCRIPTIONS ALERTS HELP Keywords GO Advanced » Institution: DeepDyve Sign In as Member / Individual User Name Password Sign In Correction to “Pharmacological Characterization of Olodaterol, a Novel Inhaled β 2 -Adrenoceptor Agonist, Exerting a 24-Hour-Long Duration of Action in Preclinical Models” In the above article [Bouyssou T, Casarosa P, Naline E, Pestel S, Konetzki I, Devillier P, and Schnapp A (2010) J Pharmacol Exp Ther <h3>334:</h3> 53–62 ], the authors have recently identified a mistake in the calculation of parts of the functional selectivity data in the originally published article. The selectivity data for olodaterol in the Abstract and in Table 3 , and the selectivity ratios for formoterol, salmeterol, and isoprenaline in table 3 are incorrect in the original article. In the Abstract and in Table 3 , the correct olodaterol β 2 selectivity ratios for the hβ 1 - and the hβ 3 -AR should be 241 and 2299, respectively. The corrected Table 3 is given below. Please note that the